Champions Oncology Q3: study service rev record $16.6M (+32%); net loss $279k vs prior yr profit $4.5M

CHAMPIONS ONCOLOGY, INC.

2026-Q3 EPS reported -$0.04 revenue$45,590,000

Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.
GAAP net loss of $279k (incl $423k stock comp, $341k D&A) vs net income $4.5M prior year.
Adjusted EBITDA $574k, down from $5.1M prior year; cost margins compressed by outsourced radiolabeling.
Ended quarter with $7.1M cash, no debt; management reaffirms full-year positive adj. EBITDA and revenue growth.
R&D expense $2.3M, up 32% for data platform and Corellia investments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2026, ended January 31, 2026 results: revenue $16.6 million, net income $279,000. Guidance reaffirmed.

Period: third quarter of fiscal 2026, ended January 31, 2026
Revenue: $16.6 million
Net income: $279,000
Guidance: reaffirmed
Result: reported results

Exact text from the filing

reference in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $16.6 Million Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year Hackensack, NJ – March 12 , 2026 – Champions Oncology, Inc.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

CHAMPIONS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-017259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.